Research in the area of GABAB receptor PAMs may lead to the development of new potentially useful drugs for the treatment of a series of diseases and syndromes, including anxiety, alcohol, nicotine and cocaine dependence, osteoarthritic pain, chronic nociceptive pain, and gastro-esophageal reflux disease.The mode of action displayed by these novel therapeutic agents suggests that they may be devoid of drawbacks that characterize full agonists, such as receptor desensitization, tolerance, muscle-relaxant effects, hypothermia, and central and gastrointestinal side effects.
Researchers involved
- Valentina Pedani - Ph.D. student